Lux kicks off trial for uveitis treatment

Article

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211.

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211, a next-generation calcineurin inhibitor, for the treatment of uveitis.

The trial, LUMINATE (Lux Uveitis Multicentre Investigation of a New Approach to TreatmEnt), consists of three controlled, double masked studies investigating the use of LX211 in different forms of active uveitis and in maintaining control in patients with quiescent disease.

The company expects to enrol more than 500 patients at approximately 45 sites across North America, Europe and India. Efficacy will be measured at six months by assessing the degree of inflammation in the anterior and posterior segments of the eye.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.